Anlon Healthcare Ltd

Anlon Healthcare Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Anlon Healthcare Ltd

₹ 169 0.50%
28 Nov - close price
anlon.in BSE: 544497 NSE: AHCL
About

Incorporated in 2013, Anlon Healthcare Limited is a chemical manufacturing company engaged in the manufacturing of Pharma Intermediates and active pharmaceutical ingredients (APIs).[1]

Key Points

Business Profile[1]
Anlon Healthcare is a chemical manufacturing company engaged in:
a) Pharmaceutical Intermediates – high-purity intermediates used as raw material/starting material in APIs.
b) Active Pharmaceutical Ingredients (APIs) – raw material for finished dosage formulations (tablets, capsules, ointments, syrups, etc.), nutraceuticals, personal care, and veterinary products.
c) It recently expanded into custom manufacturing services for complex/novel chemical compounds, including high-purity chemicals.

Website BSE NSE - BE
  • Market Cap ₹ 896 Cr.
  • Current Price ₹ 169
  • High / Low ₹ 173 / 87.0
  • Stock P/E 32.9
  • Book Value ₹ 40.3
  • Dividend Yield 0.00 %
  • ROCE 24.8 %
  • ROE 40.4 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 51.9%

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company might be capitalizing the interest cost
  • Company has high debtors of 228 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE IPO

Edit Columns
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Jun 2024 Sep 2024 Jun 2025 Sep 2025
37.83 24.17 33.30 52.20
30.98 16.65 27.06 38.46
Operating Profit 6.85 7.52 6.24 13.74
OPM % 18.11% 31.11% 18.74% 26.32%
0.06 0.05 0.01 0.03
Interest 0.98 0.93 0.82 0.87
Depreciation 0.47 0.47 0.43 0.45
Profit before tax 5.46 6.17 5.00 12.45
Tax % 16.85% 57.86% 29.20% 25.14%
4.54 2.59 3.55 9.32
EPS in Rs 2.84 0.65 0.89 1.75
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
16 57 113 66 120
21 52 100 51 88
Operating Profit -5 6 13 16 33
OPM % -32% 10% 11% 24% 27%
0 0 0 0 0
Interest 3 4 4 4 4
Depreciation 2 2 2 2 2
Profit before tax -10 -0 7 10 27
Tax % 3% 0% 17% 1% 24%
-10 -0 6 10 21
EPS in Rs -8.53 -0.09 4.85 6.04 5.15
Dividend Payout % 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 28%
TTM: 81%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 473%
TTM: 112%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: 52%
Last Year: 40%

Balance Sheet

Figures in Rs. Crores

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 12 12 12 16 40 53
Reserves -10 -10 -5 5 41 161
54 62 70 81 67 58
16 21 34 26 34 37
Total Liabilities 71 85 112 128 181 309
29 27 26 27 23 22
CWIP 0 0 0 0 0 0
Investments 0 2 4 1 1 18
43 56 82 100 158 269
Total Assets 71 85 112 128 181 309

Cash Flows

Figures in Rs. Crores

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
-15 -2 -3 -3 -23
-2 -0 -0 -3 3
16 3 2 8 19
Net Cash Flow -2 1 -1 2 -1

Ratios

Figures in Rs. Crores

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 132 130 142 213 228
Inventory Days 669 225 112 452 246
Days Payable 409 128 105 217 96
Cash Conversion Cycle 392 226 149 448 377
Working Capital Days 185 163 122 261 292
ROCE % 7% 15% 15% 25%

Shareholding Pattern

Numbers in percentages

35 Recently
Sep 2025
52.68%
2.83%
44.49%
No. of Shareholders 12,464

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

No data available.

DRHP

Concalls